Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $7.15, up 21.8% from the year before. Over ten years it grew -0.2% a year on average. The highest annual figure on record is $10.63 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.15 | +21.8% |
| FY2024 | Dec 31, 2024 | $5.87 | -17.3% |
| FY2023 | Dec 31, 2023 | $7.10 | +124.0% |
| FY2022 | Dec 31, 2022 | $3.17 | -70.2% |
| FY2021 | Dec 31, 2021 | $10.63 | +202.0% |
| FY2020 | Dec 31, 2020 | $3.52 | -30.4% |
| FY2019 | Dec 31, 2019 | $5.06 | -5.9% |
| FY2018 | Dec 31, 2018 | $5.38 | +65.5% |
| FY2017 | Dec 31, 2017 | $3.25 | +16.1% |
| FY2016 | Dec 31, 2016 | $2.80 | -61.6% |
| FY2015 | Dec 31, 2015 | $7.29 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.71 | +122.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.06 | +60.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.59 | +96.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.11 | -61.9% |
| Q2 FY2022 | Jun 30, 2022 | $0.77 | -76.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.28 | +54.2% |
| Q2 FY2020 | Jun 30, 2020 | $0.81 | – |
| Q2 FY2019 | Jun 30, 2019 | $2.91 | – |
| Q2 FY2018 | Jun 30, 2018 | $3.31 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.83 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?